Dry, arid and remote farming regions are vulnerable to water shortages, but scientists are working on a promising new solution.
As scientists have searched for solutions, an alternative water supply has been hiding in plain sight: Water vapor in the atmosphere. It is abundant, available, and endlessly renewable, just waiting for the moment that technological innovation and necessity converged to make it fit for use. Now, new super-moisture-absorbent gels developed by Yu and a team of researchers can pull that moisture from the air and bring it into soil, potentially expanding the map of farmable land around the globe to dry and remote regions that suffer from water shortages.
"This opens up opportunities to turn those previously poor-quality or inhospitable lands to become useable and without need of centralized water and power supplies," Yu said.
A renewable source of freshwater
The hydrogels are a gelatin-like substance made from synthetic materials. The gels activate in cooler, humid overnight periods and draw water from the air. During a four-week experiment, Yu's team observed that soil with these gels provided enough water to support seed germination and plant growth without an additional liquid water supply. And the soil was able to maintain the moist environment for more than a month, according to Yu.
The super absorbent gels developed at the University of Texas at Austin.
Xingyi Zhou, UT Austin
"It is promising to liberate underdeveloped and drought areas from the long-distance water and power supplies for agricultural production," Yu said.
Crops also rely on fertilizer to maintain soil fertility and increase the production yield, but it is easily lost through leaching. Runoff increases agricultural costs and contributes to environmental pollution. The interaction between the gels and agrochemicals offer slow and controlled fertilizer release to maintain the balance between the root of the plant and the soil.
The possibilities are endless
Harvesting atmospheric water is exciting on multiple fronts. The super-moisture-absorbent gel can also be used for passively cooling solar panels. Solar radiation is the magic behind the process. Overnight, as temperatures cool, the gels absorb water hanging in the atmosphere. The moisture is stored inside the gels until the thermometer rises. Heat from the sun serves as the faucet that turns the gels on so they can release the stored water and cool down the panels. Effective cooling of the solar panels is important for sustainable long-term power generation.
In addition to agricultural uses and cooling for energy devices, atmospheric water harvesting technologies could even reach people's homes.
"They could be developed to enable easy access to drinking water through individual systems for household usage," Yu said.
Next steps
Yu and the team are now focused on affordability and developing practical applications for use. The goal is to optimize the gel materials to achieve higher levels of water uptake from the atmosphere.
"We are exploring different kinds of polymers and solar absorbers while exploring low-cost raw materials for production," Yu said.
The ability to transform atmospheric water vapor into a cheap and plentiful water source would be a game-changer. One day in the not-too-distant future, if climate change intensifies and droughts worsen, this innovation may become vital to our very survival.
AI was integral to creating Moderna's mRNA vaccine against COVID.
But the truth is that before ChatGPT nabbed the public’s attention, AI was already here, and it was doing more important things than writing essays for lazy college students. Case in point: It was key to saving the lives of tens of millions of people.
AI-designed mRNA vaccines
As Dave Johnson, chief data and AI officer at Moderna, told MIT Technology Review‘s In Machines We Trust podcast in 2022, AI was integral to creating the company’s highly effective mRNA vaccine against COVID. Moderna and Pfizer/BioNTech’s mRNA vaccines collectively saved between 15 and 20 million lives, according to one estimate from 2022.
Johnson described how AI was hard at work at Moderna, well before COVID arose to infect billions. The pharmaceutical company focuses on finding mRNA therapies to fight off infectious disease, treat cancer, or thwart genetic illness, among other medical applications. Messenger RNA molecules are essentially molecular instructions for cells that tell them how to create specific proteins, which do everything from fighting infection, to catalyzing reactions, to relaying cellular messages.
Johnson and his team put AI and automated robots to work making lots of different mRNAs for scientists to experiment with. Moderna quickly went from making about 30 per month to more than one thousand. They then created AI algorithms to optimize mRNA to maximize protein production in the body — more bang for the biological buck.
For Johnson and his team’s next trick, they used AI to automate science, itself. Once Moderna’s scientists have an mRNA to experiment with, they do pre-clinical tests in the lab. They then pore over reams of data to see which mRNAs could progress to the next stage: animal trials. This process is long, repetitive, and soul-sucking — ill-suited to a creative scientist but great for a mindless AI algorithm. With scientists’ input, models were made to automate this tedious process.
“We don’t think about AI in the context of replacing humans,” says Dave Johnson, chief data and AI officer at Moderna. “We always think about it in terms of this human-machine collaboration, because they’re good at different things. Humans are really good at creativity and flexibility and insight, whereas machines are really good at precision and giving the exact same result every single time and doing it at scale and speed.”
All these AI systems were in put in place over the past decade. Then COVID showed up. So when the genome sequence of the coronavirus was made public in January 2020, Moderna was off to the races pumping out and testing mRNAs that would tell cells how to manufacture the coronavirus’s spike protein so that the body’s immune system would recognize and destroy it. Within 42 days, the company had an mRNA vaccine ready to be tested in humans. It eventually went into hundreds of millions of arms.
Biotech harnesses the power of AI
Moderna is now turning its attention to other ailments that could be solved with mRNA, and the company is continuing to lean on AI. Scientists are still coming to Johnson with automation requests, which he happily obliges.
“We don’t think about AI in the context of replacing humans,” he told the Me, Myself, and AI podcast. “We always think about it in terms of this human-machine collaboration, because they’re good at different things. Humans are really good at creativity and flexibility and insight, whereas machines are really good at precision and giving the exact same result every single time and doing it at scale and speed.”
Moderna, which was founded as a “digital biotech,” is undoubtedly the poster child of AI use in mRNA vaccines. Moderna recently signed a deal with IBM to use the company’s quantum computers as well as its proprietary generative AI, MoLFormer.
Moderna’s success is encouraging other companies to follow its example. In January, BioNTech, which partnered with Pfizer to make the other highly effective mRNA vaccine against COVID, acquired the company InstaDeep for $440 million to implement its machine learning AI across its mRNA medicine platform. And in May, Chinese technology giant Baidu announced an AI tool that designs super-optimized mRNA sequences in minutes. A nearly countless number of mRNA molecules can code for the same protein, but some are more stable and result in the production of more proteins. Baidu’s AI, called “LinearDesign,” finds these mRNAs. The company licensed the tool to French pharmaceutical company Sanofi.
Writing in the journal Accounts of Chemical Research in late 2021, Sebastian M. Castillo-Hair and Georg Seelig, computer engineers who focus on synthetic biology at the University of Washington, forecast that AI machine learning models will further accelerate the biotechnology research process, putting mRNA medicine into overdrive to the benefit of all.
This article originally appeared on Big Think, home of the brightest minds and biggest ideas of all time.
